In the midst of the late December holiday rush, employers were facing a thin talent market complicated by pandemic-driven uncertainty. Then, adding insult to injury, timekeeping and payroll went down ...

On the heels Kronos Bio’s decision to can its last remaining clinical asset earlier this month, the company said it would roll out “significant expense reduction strategies” to buy itself more time.

Kronos has been a fixture in the HR tech space for decades. The company was founded in 1977 and has clearly grown well beyond its original time clock technology. Today, the firm has HCM software and ...

Kronos is a type of Trojan, which itself is a type of malware pretending to be something else — like a harmless email attachment — but is actually something far nastier ready to infect a victim’s ...

Kronos, a multinational workforce management platform, has been hit by a ransomware attack that the company said could force its system offline for several weeks. According to parent company Ultimate ...

But that doesn't mean long term investors can avoid big losses. For example the Kronos Worldwide, Inc. (NYSE:KRO) share price dropped 69% over five years. That's not a lot of fun for true believers.

Aron Ain’s first job in the late 1970s at Kronos, the workforce management company based in Lowell, Massachusetts, was to walk the streets of Boston, asking companies if he could install a new kind of ...

Our team tests, rates, and reviews more than 1,500 products each year to help you make better buying decisions and get more from technology. Kronos Workforce Ready is highly configurable, affordable ...

Effective July 16, 2024, Kronos Worldwide, Inc. (“Kronos”) has acquired the 50% joint venture interest in Louisiana Pigment Company, L.P. (“LPC”) previously held by Venator Investments, Ltd. Prior to ...

The average one-year price target for Kronos Worldwide (NYSE:KRO) has been revised to $6.12 / share. This is a decrease of 11.11% from the prior estimate of $6.88 dated November 14, 2025. The price ...

Kronos Bio is vacating its corporate headquarters amid a wider cost-cutting exercise for the struggling biotech. The company, which has been focused on developing small-molecule drugs for cancers and ...